Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1348220rdf:typepubmed:Citationlld:pubmed
pubmed-article:1348220lifeskim:mentionsumls-concept:C0024115lld:lifeskim
pubmed-article:1348220pubmed:issue4lld:pubmed
pubmed-article:1348220pubmed:dateCreated1992-5-6lld:pubmed
pubmed-article:1348220pubmed:abstractTextWe report the findings in two patients with sulfasalazine-induced pulmonary disease. The first patient developed pulmonary interstitial fibrosis after more than 4 yr of treatment for Crohn's disease. Pulmonary symptoms and chest roentgenographic and pulmonary function abnormalities gradually reversed after stopping the drug. No specific treatment was given. The second patient, who had rheumatoid arthritis without pulmonary disease, received the drug for 1 yr without experiencing any problems. Readministration seven months later resulted in the development of an acute interstitial pulmonary disease. Discontinuing the drug and treatment with corticosteroids produced rapid improvement. We discuss these patients in relation to other reports of sulfasalazine-induced pulmonary toxicity, highlighting their atypical features.lld:pubmed
pubmed-article:1348220pubmed:languageenglld:pubmed
pubmed-article:1348220pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1348220pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1348220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1348220pubmed:statusMEDLINElld:pubmed
pubmed-article:1348220pubmed:monthAprlld:pubmed
pubmed-article:1348220pubmed:issn0012-3692lld:pubmed
pubmed-article:1348220pubmed:authorpubmed-author:AtkinsonJJlld:pubmed
pubmed-article:1348220pubmed:authorpubmed-author:SmithL JLJlld:pubmed
pubmed-article:1348220pubmed:authorpubmed-author:HamadehM AMAlld:pubmed
pubmed-article:1348220pubmed:issnTypePrintlld:pubmed
pubmed-article:1348220pubmed:volume101lld:pubmed
pubmed-article:1348220pubmed:ownerNLMlld:pubmed
pubmed-article:1348220pubmed:authorsCompleteYlld:pubmed
pubmed-article:1348220pubmed:pagination1033-7lld:pubmed
pubmed-article:1348220pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:meshHeadingpubmed-meshheading:1348220-...lld:pubmed
pubmed-article:1348220pubmed:year1992lld:pubmed
pubmed-article:1348220pubmed:articleTitleSulfasalazine-induced pulmonary disease.lld:pubmed
pubmed-article:1348220pubmed:affiliationDepartment of Medicine, Northwestern University, Chicago.lld:pubmed
pubmed-article:1348220pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1348220pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1348220lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1348220lld:pubmed